Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06044493
PHASE4

MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

Sponsor: Chong Kun Dang Pharmaceutical

View on ClinicalTrials.gov

Summary

The purpose of this study is to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients after Kidney Transplant Recipients

Official title: A Multicenter, Randomization, Open-label Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of MYREPTIC-N® or MY-REPT® in Stable Patients After Kidney Transplant Recipients

Key Details

Gender

All

Age Range

19 Years - Any

Study Type

INTERVENTIONAL

Enrollment

158

Start Date

2023-11-15

Completion Date

2025-11

Last Updated

2024-12-16

Healthy Volunteers

No

Interventions

DRUG

Myreptic-N Tablet

Up to 720mg BID(total 1440mg daily), PO - Check the blood concentration of Mycophenolate at each visit

DRUG

Mycophenolate mofetil Tablet/Capsule

Up to 1g BID(total 2g daily), PO - Check the blood concentration of Mycophenolate at each visit

Locations (1)

Seoul National University Hospital

Seoul, Seoul, South Korea